Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A single-center, prospective, randomized, placebo-controlled treatment trial to evaluate oral sodium Butyrate / Butyric acid + Standard of care (SoC) vs placebo + SoC in 93 randomized children and adolescents with Inflammatory bowel disease (IBD) at the outset of the illness for 12 weeks
Interest outcome measures:
Percentage of Relapse Patients, CRP Response, Fecal Calprotectin, Pediatric Ulcerative Colitis Activity Index (PUCAI) and Pediatric Crohn’s Disease Activity Index (PCDAI) Scores
Conclusion:
Sodium butyrate supplementation for 12 weeks proved effective as an additional treatment in children and adolescents newly diagnosed with IBD.
see…